Neoadjuvant chemotherapy for osteosarcoma of the extremity

G. Bacci, D. Springfield, R. Capanna, P. Picci, A. Guerra, U. Albissini, P. Ruggieri, R. Biagini, M. Campanacci

Research output: Contribution to journalArticlepeer-review


Eighty-five patients with nonmetastatic, highgrade osteosarcoma of an extremity recieved intravenous methotrexate and intraarterial cisplatinum and then a definitive surgical resection. The preliminary results suggest that preoperative chemotherapy with a delayed surgical resection is as safe as immediate surgery. More patients are candidates for limb salvage after chemotherapy. The tumor response to the preoperative chemotherapy also has prognostic value. Reducing the postoperative chemotherapy can be dangerous. A high dose methotrexate may not be necessary.

Original languageEnglish
Pages (from-to)268-276
Number of pages9
JournalClinical Orthopaedics and Related Research
Issue number224
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery


Dive into the research topics of 'Neoadjuvant chemotherapy for osteosarcoma of the extremity'. Together they form a unique fingerprint.

Cite this